BACKGROUND: Adverse events induced by intravesical bacillus Calmette-Guérin (BCG) to treat high-grade non-muscle-invasive bladder cancer (NMIBC) often lead to treatment discontinuation. The EAU-RF NIMBUS trial found a reduced number of standard-dose BCG instillations to be inferior with the standard regimen. Nonetheless, it remains important to evaluate whether patients in the reduced BCG treatment arm had better quality of life (QoL) due to a possible reduction in toxicity or burden. OBJECTIVE: To evaluate whether patients in the EAU-RF NIMBUS trial experienced better QoL after a reduced BCG instillation frequency. DESIGN SETTING AND PARTICIPANTS: A total of 359 patients from 51 European sites were randomized to one of two treatment arms between December 2013 and July 2019. The standard frequency arm (n = 182) was 6 weeks of BCG induction followed by 3 weeks of maintenance at months 3, 6, and 12. The reduced frequency arm (n = 177) was BCG induction at weeks 1, 2, and 6, followed by maintenance instillations at weeks 1 and 3 of months 3, 6, and 12. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Analyses were performed using an intention-to-treat analysis and a per-protocol analysis. QoL was measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 version 3.0 (QLQ-C30 v.03) prior to the first and last instillations of each BCG cycle. Group differences were determined using linear regression corrected for QoL at baseline. Differences in QoL over time were tested for significance using a linear mixed model. Side effects were recorded by the treating physician using a standardized form. Chi-square tests were used to compare the side-effect frequency between the arms. RESULTS AND LIMITATIONS: There were no significant differences in the means of each QoL scale between the two arms. There were also no significant changes over time in all QoL domains for both arms. However, differences in the incidence of general malaise at T1 (before the last induction instillation), frequency, urgency, and dysuria at T7 (before the last maintenance instillation) were detected in favor of the reduced frequency arm. CONCLUSIONS: Reducing the BCG instillation frequency does not improve the QoL in NMIBC patients despite lower storage symptoms. PATIENT SUMMARY: In this study, we evaluated whether a reduction in the number of received bacillus Calmette-Guérin instillations led to better quality of life in patients with high-grade non-muscle-invasive bladder cancer. We found no difference in the quality of life between the standard and the reduced bacillus Calmette-Guérin instillation frequency. We conclude that reducing the number of instillations does not lead to better quality of life in patients with high-grade non-muscle-invasive bladder cancer.

Department of Urology Acıbadem University Istanbul Turkey

Department of Urology Hospital Edouard Herriot Lyon France

Department of Urology Hospital Motol 2nd Faculty of Medicine Charles University Prague Czech Republic

Department of Urology Hospital Universitario La Paz Madrid Spain

Department of Urology Jena University Hospital Jena Germany

Department of Urology Radboud University Medical Center Nijmegen The Netherlands

Department of Urology University Hospitals Leuven Leuven Belgium

EAU Research Foundation Arnhem The Netherlands

London UK

Skåne University Hospital Lund University Lund Sweden

Urology Department Fundació Puigvert Universitat Autònoma de Barcelona Barcelona Spain

Zobrazit více v PubMed

Richters A., Aben K.K.H., Kiemeney L.A.L.M. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38:1895–1904. PubMed PMC

Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–477. PubMed

Mottet N., van den Bergh R.C.N., Briers E., et al. European Association of Urology guidelines. European Association of Urology; Arnhem, The Netherlands: 2021. EAU-ESTRO-ESUR-SIOG guidelines on cancer 2021.

Böhle A., Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology. 2004;63:682–686. PubMed

Böhle A., Jocham D., Bock P.R. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003;169:90–95. PubMed

Brausi M., Oddens J., Sylvester R., et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65:69–76. PubMed

Sylvester R.J., Brausi M.A., Kirkels W.J., et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol. 2010;57:766–773. PubMed PMC

Oddens J., Brausi M., Sylvester R., et al. Final Results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63:462–472. PubMed

Grimm M.O., van der Heijden A.G., Colombel M., et al. Treatment of high-grade non–muscle-invasive bladder carcinoma by standard number and dose of BCG instillations versus reduced number and standard dose of BCG instillations: results of the European Association of Urology Research Foundation randomised phase III clinical trial “NIMBUS”. Eur Urol. 2020;78:690–698. PubMed

World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects. J Med Liban. 1994;42:88–89. PubMed

Pocock S.J. John Wiley & Sons; 2013. Clinical trials: a practical approach.

Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376. PubMed

WHO . World Health Organization; Geneva, Switzerland: 1979. WHO handbook for reporting results of cancer treatment.

Yokomizo A., Kanimoto Y., Okamura T., et al. Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Guérin instillation therapy for nonmuscle invasive bladder cancer. J Urol. 2016;195:41–46. PubMed

Gontero P., Oderda M., Mehnert A., et al. The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial. J Urol. 2013;190:857–862. PubMed

Waked R., Choucair J., Chehata N., Haddad E., Saliba G. Intravesical bacillus Calmette-Guérin (BCG) treatment's severe complications: a single institution review of incidence, presentation and treatment outcome. J Clin Tuberc Other Mycobact Dis. 2020;19 PubMed PMC

Zimmermann K., Mostafaei H., Heidenreich A., Schmelz H.U., Shariat S.F., Mori K. Health-related quality of life in bladder cancer patients: general and cancer-specific instruments. Part 1. Curr Opin Urol. 2021;31:297–303. PubMed

Ripping T.M., Westhoff E., Aaronson N.K., et al. Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 questionnaire module for patients with non-muscle-invasive bladder cancer. J Patient Rep Outcomes. 2021;5:96. PubMed PMC